Here are the 10-K annual reports from Masimo Corporation (MASI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MASI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MASI filings page.
Masimo Corporation filed Amendment No. 1 to its Form 10-K for fiscal 2025 to add Part III information on directors, executive officers, governance and compensation instead of incorporating a future proxy statement. The filing details a refreshed board and leadership team, including new CEO Catherine Szyman and several recently hired senior executives.
It describes a pay program heavily weighted to performance: 2025 annual bonuses for most named executives were funded at 113% of target, while performance stock units granted in 2023 vested at only 18% of target, reflecting tough three‑year goals. The amendment also notes a pending merger under a February 16, 2026 agreement for Masimo to be acquired by Danaher, subject to regulatory and stockholder approvals, after which Masimo’s stock is expected to be delisted.
Masimo Corporation’s annual report outlines a major strategic shift centered on its core medical-technology platform and a pending sale of the company. Masimo develops noninvasive monitoring, hospital automation and connectivity products built on its Masimo SET and rainbow platforms, sold to hospitals and OEM partners worldwide.
The company completed the sale of its non‑healthcare consumer audio business, Sound United, to Harman International, a Samsung subsidiary, on September 23, 2025, sharpening its focus on healthcare. Masimo has also agreed to be acquired by Danaher: each outstanding share will be converted into the right to receive $180.00 in cash, without interest, if the merger closes.
The merger, expected in the second half of 2026, remains subject to stockholder approval and multiple regulatory clearances, and the risk section highlights that delays, failure to obtain approvals, and deal uncertainty could adversely affect operations. The filing also details extensive regulatory, reimbursement, privacy, and anti‑kickback frameworks governing Masimo’s business, plus key risks tied to intellectual property, OEM and GPO relationships, and government oversight.